California stem cell agency in appeal over constitutionality

12 February 2007

The First District Court of Appeals in San Francisco, California is to decide, after a hearing on February 14, whether the USA's largest state has the authority, under its constitution, to establish a stem cell research facility.

In 2004, Proposition 71 was carried in a statewide referendum, approving the foundation of the California Institute for Regenerative Medicine, at a cost of $3.0 billion over 10 years. The intention of the venture's supporters was to provide an alternative route for public funding of human embryonic stem cell research, which is restricted at the federal level by President George W Bush's veto (Marketletter January 22).

A ruling by the Alameda Superior Court found that the Institute's funding was constitutional, however, the state of California has not issued bonds to finance the new agency until the litigation process is exhausted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight